Stealth BioTherapeutics Looks Ahead To Phase III In Mitochondrial Disease
Stealth BioTherapeutics is planning Phase III trials on the back of positive Phase II data for its lead product elamipretide in the rare indication of mitochondrial dysfunction, a disease for which there no currently approved treatments.
You may also be interested in...
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.